iOmx Therapeutics raises €40 million in fundraising led by MPM Capital and Sofinnova

Omx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on novel immune checkpoint targets, have closed a Series A financing round totaling EUR 40 million. MPM Capital and Sofinnova Partners co-led the round, and were joined by Wellington Partners and Merck Ventures.

iOmx focuses on the development of first-in-class cancer therapeutics addressing next-generation immune checkpoints. By systematically screening human tumor cells, the company has already identified a number of new targets and analyzed their mode of action. The proceeds of the financing round will be used to advance several proprietary product candidates up to initial clinical proof-of-concept.

iOmx was founded based on work from the laboratory of oncology expert and co-founder Philipp Beckhove, previously at the German Cancer Research Center, Heidelberg, and now at the RCI Regensburg Center for Interventional Immunology. The company’s innovative screening platform was developed by co-founder Nisit Khandelwal, SVP of Research. Additional co-founders include highly experienced biotech executives and internationally renowned cancer specialists Patrick Baeuerle, Elmar Maier (CBO), and Sebastian Meier-Ewert (CEO).

“The development of checkpoint inhibitors represents a major advance in the treatment of certain cancers. However, despite some truly transformative successes, to date only a minority of patients benefit from existing treatment options. We aim to bring the advances in immuno-oncology to a greater proportion of cancer patients,” said Sebastian Meier-Ewert, CEO of iOmx. “Therefore, we are proud to have attracted such an outstanding international investor base. The round was significantly oversubscribed, highlighting the expectation that immune checkpoint-based cancer therapeutics have great potential for changing the oncology landscape – and iOmx is excellently positioned to play a leading role in this field.”

“We are thrilled to back iOmx, together with such a high profile investor syndicate. The company combines all the key features we are looking for when investing: an exceptional management team, world class science, and a market breaking technology platform that has the potential to build a strong pipeline of proprietary and more efficacious cancer therapeutics,” said Henrijette Richter, Chairwoman of iOmx´ Board of Directors and Partner at Sofinnova Partners.


About iOmx Therapeutics
iOmx (www.iomx.de) focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoints on cancer cells. The company’s proprietary platform systematically screens tumor cells for specific immune checkpoint modulators, which allow targeting the tumor´s immune resistance mechanisms. iOmx is building a pipeline of promising cancer immunotherapeutics based on novel, proprietary targets with a known mode of action. Founded in March 2016 based on the work of its scientific founders Philipp Beckhove and Nisit Khandelwal conducted at the German Cancer Research Center, the company has raised EUR 40 million in early July 2016 from MPM Capital (both its BV2014 and UBS Oncology Impact Funds), Sofinnova Partners, Wellington Partners and Merck Ventures and is based in Martinsried / Munich, Germany.

 

Source : Sofinova Partners Press Release

Email this to someoneShare on LinkedInShare on FacebookTweet about this on TwitterShare on Google+